Pediatric Survivorship: Considerations Following CAR T-Cell Therapy.
Clinical journal of oncology nursing
BACKGROUND: This article presents an overview of pediatric relapsed and refractory acute lymphoblastic leukemia (ALL) and chimeric antigen receptor (CAR) T-cell therapy in pediatric patients.
OBJECTIVES: Acute and chronic post-CAR T-cell effects and considerations are discussed, along with survivorship considerations.
METHODS: A case study illustrates the identification and management of physiologic and psychosocial sequelae.
FINDINGS: B-cell aplasia, hypogammaglobulinemia, infections, and cumulative effects of CAR T-cell therapy and other treatments are a concern in the pediatric population. Unique to pediatric and young adult survivors of childbearing potential are implications for post-treatment fertility. Financial toxicities and psychosocial needs require a family-centered approach to interventions that address the impact of CAR T-cell therapy not only on the patient, but also on caregivers and siblings.
Humans, Immunotherapy, Adoptive, Pediatrics, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Survival Rate
Callahan, C., Barry, A., Fooks-Parker, S., Smith, L., Baniewicz, D., & Hobbie, W. (2019). Pediatric Survivorship: Considerations Following CAR T-Cell Therapy.. Clinical journal of oncology nursing, 23 (2), 35-41. https://doi.org/10.1188/19.CJON.S1.35-41